Detalhe da pesquisa
1.
Telemedicine with special focus on allergic diseases and asthma-Status 2022: An EAACI position paper.
Allergy
; 79(4): 777-792, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38041429
2.
Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.
Allergy
; 78(4): 968-983, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36325824
3.
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper.
Allergy
; 78(11): 2851-2874, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37814905
4.
Omics technologies in allergy and asthma research: An EAACI position paper.
Allergy
; 77(10): 2888-2908, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35713644
5.
EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old.
Allergy
; 77(1): 17-38, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34324716
6.
Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference.
Allergy
; 77(10): 3002-3014, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35567393
7.
Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air® real-world data.
Allergy
; 77(9): 2699-2711, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35258105
8.
Development and validation of combined symptom-medication scores for allergic rhinitis.
Allergy
; 77(7): 2147-2162, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34932829
9.
ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper.
Allergy
; 76(6): 1624-1628, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33378789
10.
EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis.
Allergy
; 76(4): 988-1009, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538044
11.
Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics.
Allergy
; 76(4): 1199-1212, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32813887
12.
Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines.
Allergy
; 76(1): 45-58, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32691892
13.
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines.
Allergy
; 76(1): 59-70, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32767573
14.
EAACI Biologicals Guidelines-Recommendations for severe asthma.
Allergy
; 76(1): 14-44, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32484954
15.
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.
Allergy
; 76(6): 1640-1660, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33811364
16.
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines.
Allergy
; 76(8): 2337-2353, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33683704
17.
COVID-19 pandemic and allergen immunotherapy-an EAACI survey.
Allergy
; 76(11): 3504-3516, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33655519
18.
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.
Allergy
; 76(3): 648-676, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32531110
19.
Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus.
Allergy
; 76(8): 2354-2366, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730365
20.
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma.
Allergy
; 75(5): 1058-1068, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32154939